Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis

Jens F. Poschet,1 Graham S. Timmins,2 Jennifer L. Taylor-Cousar,3,4 Wojciech Ornatowski,1 Joseph Fazio,1 Elizabeth Perkett,3,5 Kari R. Wilson,6 Hongwei D. Yu,6 Hugo R. de Jonge,7 and Vojo Deretic1,5

1Department of Molecular Genetics and Microbiology, 2College of Pharmacy, Departments of 3Internal Medicine, 4Pediatrics, and 5Cell Biology and Physiology, University of New Mexico Health Science Center, Albuquerque, New Mexico; 6Department of Biochemistry and Microbiology, Joan C. Edwards School of Medicine Marshall University, Huntington, West Virginia; and 7Department of Biochemistry, Erasmus University Medical Center, Rotterdam, The Netherlands

Submitted 16 August 2006; accepted in final form 29 May 2007

Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 293: L712–L719, 2007. First published June 22, 2007; doi:10.1152/ajplung.00314.2006.—The CFTR gene encodes a chloride channel with pleiotropic effects on cell physiology and metabolism. Here, we show that increasing cGMP levels to inhibit epithelial Na+ channel activity is a therapeutic strategy in cystic fibrosis (CF). CFTR respiratory epithelial cells correct several aspects of the downstream pathology in CF. Cell culture models, using a range of CF cell lines and primary cells, showed that complementary pharmacological approaches to increasing intracellular cGMP, by elevating guanyl cyclase activity through reduced nitric oxide, addition of cell-permeable cGMP analogs, or inhibition of phosphodiesterase 5 corrected multiple aspects of the CF pathological cascade. These included correction of defective protein glycosylation, bacterial adherence, and proinflammatory responses. Furthermore, pharmacological inhibition of phosphodiesterase 5 in tissues ex vivo or in animal models improved transepithelial currents across nasal mucosa of transgenic F508del CFTR−/− mice and reduced neutrophil infiltration on bacterial aerosol challenge in Pseudomonas aeruginosa-susceptible DBA/2 mice. Our findings define phosphodiesterase 5 as a specific target for correcting a number of previously reported (39) our initial observations that hyperacidification of the trans-Golgi network (TGN) in CF respiratory epithelial cells (38), although the mechanism and signaling events linking upstream defects in CF and TGN hyperacidification remain to be delineated. The previously reported abnormally acidic TGN lumen in CF cells causes suboptimal sialyltransferase activity (38), resulting in defective sialylation of plasma membrane glycoconjugates providing neoreceptors for bacterial adherence, thus promoting chronic bacterial colonization and inflammation in the CF lung (3, 7, 22, 38). We have recently reported (39) our initial observations that hyperacidification of another intracellular compartment in CF cells, i.e., recycling endosome, is affected by cGMP levels and a phosphodiesterase activity, but the exact signaling pathway and specific components involved have not been identified.

Here, we present siRNA knockdown-based experiments demonstrating directly that ENaC activity is responsible for organellar hyperacidification in CF cells and show that phosphodiesterase 5 (PDE5) can be specifically targeted to normalize lumenal pH in the TGN of CF respiratory epithelial cells. We demonstrate the causal relationships in CF cells (see model in Fig. 1), starting with their reduced nitric oxide levels, leading to lower than normal cGMP levels and ending with the effects on hyperacidification in CF based on unrepressed ENaC due to lower cGMP levels. We furthermore show that the PDE5 inhibitor sildenafil corrects the majority of the known pathological defects in CF by reducing bacterial adhesion to respiratory epithelial cells and normalizing the overexuberant proinflammatory response to bacterial products. Inhibition of PDE5 provides beneficial effects in ex vivo studies with respiratory mucosal tissue from transgenic mice and in an aerosol infection model with mice susceptible to Pseudomonas aeruginosa, the principal bacterial pathogen in CF.
charge, permitting extended activity of H+ membrane potential, which shuts down H+-dependent inhibition of ENaC. This results in Na+ or inhibition of cGMP-specific phosphodiesterase PDE5, results in a cGMP-correction of organellar pH, even in the absence of CFTR in CF cells, from Na+. The following compounds were from BIOMOL Research Laboratories (16) and used at therapeutically relevant concentrations.

- 3-(E)-ethyl-2-(4-carboxyphenyl)4,4,5,5 tetramethyl-imidazoline-1-oxyl-3-oxide (NOR-4), (Z)-1-[2-(2-aminoethyl)-N-(benzylamidino)-3,5-diamino-6-(2-ammonioethylamino)diazen-1-ium-1,2-diolate (DETA-NONOate), (3-(aminomethyl)benzyl)acetamidine (1400W), a highly selective CFTR chloride channel inhibitor CFTRinh-172 (30) was from A.
- (2-ammonioethylamino)-3,5-diamino-6-(3-(aminomethyl)benzyl)acetamidine (1400W), a highly selective CFTR chloride channel inhibitor CFTRinh-172 (30) was from A.

**Methods**

**Chemicals.** Sildenafil (2) was prepared by purification as previously described (16) and used at therapeutically relevant concentrations of 300 nM (http://www.viagrard.com) with pharmacokinetics not affected by azithromycin (35), a drug frequently prescribed in CF. The following compounds were from BIOMOL Research Laboratories: N-(3-aminomethyl)benzylacetamide (1400W), a highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo (18), N-nitro-l-arginine methyl ester (lNAME), N-nitro-l-arginine methyl ester (lNAME), (±)-3-(E)-ethyl-2-(4-(E)-hydroxyximo-5-nitro-3-hexencarboxamoyl) pyridine (NOR-4), (Z)-1-[2-(2-aminoethyl)-N-(2-ammonioethylamino)lalohazen-1-ium-1,2-diolate (DETA-NONOate), 2-(4-carboxyphenyl)4,4,5,5 tetramethyl-imidazoline-1-oxyl-3-oxide-TGN (CPTIO), guanylin, protoporphyrin IX, 1H-oxadiazolo[4,3-a]-quinoxalin-1-one (ODQ), 4H-8-bromo-1,2,4-oxadiazolo(3,4-d)benz(b)(1,4)oxazin-1-one (NS-2080), 3-isobutyl-l-methylxanthine (IBMX), (±)-4-[3-(cyclopentoxy)-4-methoxophenyl]-2-pyrrolidinone (rolipram), 4-[3-(4-methyl-l-enedioxy)benzyl]aminol-6-chloroazinoline (MBCQ) (17), 2-(2-propoxyphenyl)-8-azahypoxanthine (Zaprinast), 8-Br-cGMP, and dibutyl-cGMP. N-(benzylaminodio)-3,5-diamino-6-chloropyrazine-carboxamide (benzamil) was from Alexis. The specific CFTR chloride channel inhibitor CFTRinh-172 (30) was from A. Verkman. 5-Cyclopropyl-2-[1-(2-fluoro-benzyl)]-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY-41-2272), an NO-independent activator of NO-sensitive guanylyl cyclase (5), was from Sigma.

**Cells and tissue culture.** IB3–1 is a bronchial epithelial cell line derived from a CF patient with a DF508/W128X CFTR mutant genotype (55). S9 is a derivative of IB3–1 corrected for chloride conductance by stable transfection with a functional CFTR. The cells were maintained in LHC-8 media (Biosource). The CF cell line CFBE41o– (DF508/DF508) and normal human bronchial epithelial cells16HBEo– (from D. Gruenert) were maintained in complete MEM-media (Gibco, Life Technologies). The normal human tracheal cell line 9HTE0–, transfected with pCep-R or pCep, were from P. Davis and were maintained in complete DMEM (Gibco, Life Technologies). Primary bronchial epithelial cells were from Clonetics (NHBE) or from P. Karp (CF lung transplants) and were maintained in supplemented BEBM (Cambrex, MD). CFTR genotyping was carried out by PCR and oligonucleotide ligation assay. Primary cells and multiple cell lines, as genetically or otherwise matched pairs (CF and normal phenotypes), when available, were used. In this study represent nearly all published lines available and developed for CF research by independent groups, with the exceptions of 1) CFT1 cells (36), since their culture requires cholea toxin added to the medium and consequently were not included in this study; and 2) CuF1 cell lines (54), since these cells could not be used in our Pseudomonas adhesion assay since the monolayers were highly sensitive to addition of bacteria.

**Transfections and microscopy.** TGN38 fusion with pH-sensitive GFP (33) was from J. Rothman. Cells were transfected with 1 μg/ml DNA using Effectene (Qiagen) for 48 h. Ratiometric pH determination by fluorescence microscopy in live cells was carried out as previously described (33, 38, 40). A pH standard curve was generated by collapsing the pH-gradient by incubating cells in 10 mM monensin and 10 mM nigericin for 30 min at 37°C in buffer A at pH 7.4, 6.5, or 5.5, and ratios were recorded for internal standards. Fluorescence images were taken on excitation at 410 and 470 nm (6 consecutive exposures). Three regions of interest were selected, and the standard curve was plotted as averaged 410:470 ratio values for a given buffer pH. The term hyperacidification for TGN in CF cells, is used relative to the less acidic pH in normal or CFTR-corrected cells. It is known that the pH of TGN is elevated in airway epithelial cells compared with a number of other cell types (49). Confocal fluorescence microscopy of fixed samples was carried out on Zeiss 510 META microscope. Endogenous ENaC was revealed by immunoblots or immunofluorescence (ENaCx antibody from Diagnost).

**Manipulation of signaling pathways affecting pH of TGN in CF cells.** All compounds were diluted in buffer A before addition. NO donors DETA-NONOate or N0-4 were added for 20 min at a concentration that initially released 0.1 mM NO. Nitric oxide synthase was inhibited in S9 cells by incubation of cells in 10 mM monensin and 10 mM nigericin for 30 min at 37°C in buffer A and with 300 nM sildenafil. S9 cells were incubated with 0.6 M IBMX (23), 100 nM MBCQ, 10 μM rolipram, 1 or 50 μM zanapin, and 300 nM sildenafil, were added for 60 min at 37°C. Ten micromolar acetylstrophantedine was added for 1 h before addition of 300 nM sildenafil. S9 cells were incubated with 0.6 M CFTRinh-172 for 15 min following by three 10-min washes with buffer A. To block intracellular ENaC, cells were treated for 20 min with 10 μM benzamil, a membrane permeate derivative of the sodium channel blocker amiloride. ENaCx-a and PDE5 knockdown with siRNA. All siRNAs were from Dr. dramacon and generated using specific algorithms for exclusive

Fig. 1. Model of defects in cystic fibrosis (CF) lung epithelial cells. A: in normal cells, a functional CFTR inhibits epithelial sodium channel (ENAC). As a result, positive charge from Na+ (bold), pumped into the lumen by Na+-K+ ATPase, builds up membrane potential, which shuts down H+-ATPase, thus maintaining normal (slightly acidic) pH in the trans-Golgi network (TGN) of respiratory epithelial cells. B: in CF cells, in the absence of CFTR, ENaC open probability increases, thus allowing efflux of Na+ from the TGN lumen, which dissipates the positive charge, permitting extended activity of H+-ATPase, and results in hyperacidification of the organellar lumen. C: addition of exogenous nitric oxide (NO-) or inhibition of cGMP-specific phosphodiesterase PDE5, results in a cGMP-dependent inhibition of ENAC. This result in Na+ build-up (bold) in the correction of organellar pH even in the absence of CFTR in CF cells, normalizing organellar acidification. When Na+-K+ ATPase is inhibited by acetylstrophantedine, reduced amounts of Na+ are pumped into the lumen (as indicated by parentheses), which causes hyperacidification in normal or CFTR-corrected cells. For more detailed discussion, see supplementary data available online at the American Journal of Physiology–Lung Cellular and Molecular Physiology website.
targeting. Scrambled siRNAs were used as controls. Introduction of siRNA into the cells was by Effectene. Protein knockdown was monitored by immunoblotting.

Sialylation of GM1 in CF lung epithelial cells. P. aeruginosa adherence to CF lung epithelial cells, and NF-kB activation, sGM1 levels were assessed with fluorescently labeled cholera toxin, bacterial adhesion by colony counts, and NF-kB activation by luciferase assays, as previously described (38). CF and normal cells, grown postconfluence, were incubated for 48 h with 50 μM zatprim and 300 nM sildenafil. Cells were fixed and stained with fluorescently labeled cholera toxin B for 60 min at room temperature. Relative fluorescence was calculated from actual gray levels of 10 random fields from three independent experiments. Postconfluent cells, treated with 50 μM zatprim and 300 nM sildenafil, were incubated with P. aeruginosa (PAO1) at a multiplicity of infection of 1:200 in MEM media without serum or antibiotic supplements. Samples were washed three times with PBS and lysed with 0.5% TX-100. Cell associated bacteria were plated on P. aeruginosa isolation agar colonies and counted. Treatment with Pseudomonas pro-inflammatory lipopeptide (lipotoxin) LptA and NF-kB activation analysis were carried out as previously described (15).

CFTR transgenic mice mucusal tissue short-circuit current measurements in ex vivo experiments with Ussing chamber mounts. Nasal mucosa was from adult F508del Cfr+/-Eur mice (congenic FVB, with residual CFTR currents) or CFTR-/- mice (congenic FVB, Cfr knockout with no CFTR currents) (43, 48). The chambers were filled with gassed (95% O2-5% CO2) Meyler solution and the short-circuit current (Isc) measurements were started.

Animal model of P. aeruginosa aerosol infection and myeloperoxidase levels in lung tissues. DBA/2 mice (6–8 wk; Charles River Laboratories) were fed a specially formulated diet with or without sildenafil with gassed (95% O2-5% CO2) Meyler solution and the short-circuit current (Isc) measurements were started.

RESULTS

Hyperacidification of TGN in CF respiratory epithelial cells is due to abnormally low inducible NO synthase and NO levels. The levels of reduced NO in the CF lung are lower than normal (19, 25, 32). We tested the hypothesis that the NO defect in CF respiratory epithelial cells contributes to TGN hyperacidification via a NO-guanylate cyclase-cGMP cascade controlling sodium channel activity. The TGN pH was determined using the pH-sensitive GFP, as previously described (38), with Fig. 2A showing the characteristic perinuclear localization of the TGN38-phlourin GFP probe to the TGN, in keeping with prior marker colocalization studies (38). The CF lung epithelial cell line IB3-1 (55), lacking in CF transport (confirmed using halide-sensitive YFP; supplemental Fig. S1) and expressing less inducible NO synthase (iNOS) than the genetically matched CFTR-corrected IB3-1 cells (Fig. 2B–D), was treated with the NO--donors DETA-NONOate and NOR-4. This normalized the pH in the TGN (DETA-NONOate: pH 7.0 ± 0.2; NOR-4: pH 6.9 ± 0.2) (Fig. 2E). Conversely, when S9 cells were incubated with NO inhibitor l-NAME or highly specific iNOS inhibitor 1400W, the TGN in S9 (CFTR-corrected) cells (S9) (C) quantified after background corrections (D) by ratiometric determination (33, 38, 40) of organellar pH in cells transfected with TGN38 phlourin GFP (33). IB3-1 cells were treated for 20 min with DETA-NONOate or NOR-4 normalized for release of 0.1 mM NO- (n = 5). E: CFTR-corrected S9 cells were treated with 1 mM NO inhibitor l-NAME for 60 min or its inactive stereoisomer R-NAME, or with specific inducible NOS (iNOS) inhibitor 1400W at 10 μM for 20 min (n = 5). F: CF cells (IB3-1) treated with guanylate cyclase agonists: 10 μM guanylin for 30 min, 10 μM protoporphyrin IX for 90 min, or 10 μM BAY41-2272 for 60 min (n = 5). Guanylate cyclase antagonists, 10 μM ODQ and NS-2028, for 30 min counteracted pH correction by 0.1 mM DETA-NONOate (n = 5). H: membrane permeant cGMP analogs 100 μM 8-Br-cGMP (60 min) and dibutyryl-cGMP (30 min) corrected TGN pH in IB3-1 cells (n = 5).

The signaling cascade responsible for TGN hyperacidification in CF includes guanylate cyclase. Further delineation of the pathway acting downstream of NO--indicated that guanylate cyclase was involved in TGN acidification. Incubating IB3-1 cells with guanylin, a small peptide physiologically present in normal lung fluids and acting as agonist of mem-

AJPLung Cell Mol Physiol • VOL 293 • SEPTEMBER 2007 • www.ajplung.org
brane-bound guanylate cyclase, elevated the pH of the TGN in CF cells to 7.1 ± 0.4 (Fig. 2G). Protoporphyrin IX, an agonist of soluble guanylate cyclase, also increased TGN hyperacidification in IB3-1 cells (pH 7.4 ± 0.5). BAY41-2272, another soluble guanylate cyclase agonist, corrected the pH to 6.7 ± 0.1. Conversely, when the effects of the guanylate cyclase antagonists ODQ and NS-2028 were assessed in the presence of the NO-donor DETANO-NONOate, both ODQ (pH 6.1 ± 0.1) and NS-2028 (pH 6.1 ± 0.2) counteracted normalization of TGN pH in response to DETANO-NONOate (Fig. 2G).

Stimulation with cGMP normalizes TGN pH in CF cells. We next tested whether cGMP can normalize the TGN pH in CF cells. Two membrane permeant forms of cGMP, 8-Br-cGMP and dibutyryl-cGMP, corrected the hyperacidification of TGN: the pH changed from 6.1 ± 0.1 to 6.9 ± 0.2 (for 8-Br-cGMP) and to 6.8 ± 0.2 (for dibutyryl-cGMP) (Fig. 2H). Collectively, these experiments connect the NO-deficiency in CF (19, 24, 32) to organellar hyperacidification in CF respiratory epithelial cells (9, 37, 38, 40) via a guanylate cyclase signaling pathway.

Cyclic GMP-specific phosphodiesterase inhibitors correct TGN hyperacidification in CF. Based on these observations, inhibiting cellular phosphodiesterases and increasing intracellular cGMP appeared as a viable approach for pharmacological intervention in CF. Of the 11 recognized PDE families, 7 are expressed in the lung, including PDE1, PDE3-7, and PDE9 (4, 17). The cGMP-specific PDE5 is abundant in the lung and, along with the cAMP-specific PDE4 (20), represents the predominant PDE form, accounting for nearly 80% of the overall PDE activity in the airways. When IB3-1 CF cells were treated with rolipram, an inhibitor specific for PDE4 (4, 17, 20) that hydrolyzes cAMP, no change in the TGN pH was observed (Fig. 3A). Zaprinast, a precursor in the development of the drug sildenafil, an inhibitor of PDE5 (which hydrolyzes cGMP), corrected TGN hyperacidification from pH 6.1 ± 0.2 to 6.9 ± 0.1 (Fig. 3A). At higher concentrations, zaprinast inhibits PDE6 and 9 (44). Increasing zaprinast concentration led to no additional change in pH relative to the PDE5-specific action at lower zaprinast concentrations (Fig. 3A), thus suggesting that PDE6 and PDE9 had no dominant effect. The role of PDE5 was further confirmed by using PDE5-inhibitor MBCQ, which corrected TGN hyperacidification in CF cells from 6.1 ± 0.2 to 6.8 ± 0.1 (Fig. 3A). IBMX, a nonselective PDE inhibitor, with added complexity of adenosine action, increased TGN pH from 6.1 ± 0.2 (untreated control) to 6.6 ± 0.3. The chloride channel activity of CFTR is readily activated by cAMP (46); thus, in this series of experiments, we could not rule out that the effect with IBMX could be attributed to cAMP rather than to cGMP.

To confirm our pharmacological analyses, we established by immunoblotting that PDE5 is expressed in human bronchial epithelial cells (Fig. S2). Next, PDE5 knockdown using siRNA was performed. As predicted, PDE5 siRNA, but not a scrambled control siRNA, corrected TGN pH in IB3-1 cells (Fig. 3A; pH 6.7 ± 0.1 and 6.0 ± 0.1, respectively; P = 0.0008). The results with PDE inhibitors were confirmed in additional cell lines. A tracheal epithelial cell line 9HTEo−, displaying CF phenotype due to the expression of a dominant negative CFTR construct (pCep-R) (7), was treated with zaprinast (Fig. 3B). The TGN pH was corrected (pH 6.3 ± 0.1 to 6.7 ± 0.2) and matched that in the normal control (9HTEo− cells transfected with the plasmid pCep without the CFTR R-domain).

Sildenafil efficiently corrects hyperacidification in primary human epithelial cells. Sildenafil has shown promise in clinical studies for treatment of lung disease, such as primary pulmonary hypertension (42, 45). We tested this widely used FDA-approved PDE5 inhibitor, with a 240-fold greater specificity toward PDE5 than zaprinast. Sildenafil, at therapeutically relevant concentrations of 300 nM, normalized the TGN pH in IB3-1 cells, matching that of the CFTR-corrected S9 cells (Fig. 3, A and E–G). The correction of TGN hyperacidification on sildenafil treatment was confirmed in bronchial epithelial cell line CFBE41o− derived from a patient homozygous for F508 CFTR mutation (32) (Fig. 3C). Moreover, primary human bronchial epithelial cells (CFTR F508/D or F508/F508) obtained from lung transplants showed pH correction on sildenafil treatment (Fig. 3D).

Sodium transport via ENaC is responsible for TGN hyperacidification in CF. We have previously demonstrated (37, 38) that increased Na+ efflux from the TGN lumen in CF cells is responsible for the hyperacidification of this organelle in a
A candidate drug must be able to ameliorate CF epithelial cells. Inhibition of Na\(^+\)-ATPase using the membrane-permeant inhibitor benzamil, corrected the TGN hyperacidification in IB3 cells (Fig. 5D) but not cAMP (Fig. 5B) levels in primary CF lung epithelial cells. Inhibition of Na\(^+\)-K\(^+\)-ATPase using the ENaC inhibitor ENaC inhibitor macetylstrophantedine (37, 38) induced hyperacidification in CFTR-correced cells (Fig. 5C). A membrane permeant inhibitor of ENaC, benzamil, corrected the TGN hyperacidification in IB3 cells (Fig. 5D) and in primary CF cells homozygous for the F508 CFTR allele (Fig. 5E). Finally, we demonstrated that ENaC was responsible for these effects using ENaC-\(\alpha\) siRNA. ENaC-\(\alpha\) knockdown (Fig. 5F) corrected the pH of the TGN in IB3-1 cells (Fig. 5G), whereas control siRNA treatment did not. In addition, we established that chloride channel activity of CFTR did not affect TGN pH, since inhibition of CFTR Cl\(^-\) transport by a highly selective channel inhibitor, CFTRinh-172 (30), did not alter organellar pH in normal cells (Fig. 5H).

PDE5 inhibitor sildenafil corrects pathological cascade in CF epithelial cells. A candidate drug must be able to ameliorate a set of defined pathological abnormalities in CF. The disease-causing effects of TGN hyperacidification in CF are the characteristic undersialylation of plasma membrane glycoproteins and glycolipids and increased adhesion of CF pathogens, e.g., P. aeruginosa, to asialo-glycoconjugates (7, 11, 22, 27, 38), which, at later stages of advanced disease, lead to P. aeruginosa association with the mucus (50). Zapro.in and sildenafil restored siaylation in IB3-1 cells to the levels seen in the CFTR-corrected S9 cells (Fig. 6, A–C). PDE5 inhibition also corrected siaylation in another tested CF cell line (CFBE41o–), restoring it to the levels seen in 16HBE14o– normal human bronchial cells (32) (Fig. 6C). The effects of sildenafil could not be attributed to mislocalization of the sialyltransferase since it remained in the TGN (Fig. 6, D and E). Thus the correction of the siaylation defect is due to normalization of the pH at the appropriate site of sialyltransferase enzymatic action.
PDE5 inhibitors also corrected *P. aeruginosa* adhesion to CF cells. Bacterial adherence to IB-3-1 cells was reduced to the levels seen with the CFTR-corrected S9 cells (Fig. 6F). CFBE41o− cells treated with sildenafil showed a 10-fold reduction of bacterial adhesion, bringing it to levels comparable with normal bronchial cells (16HBE14o−) (Fig. 6G). Similar reduction in *P. aeruginosa* adhesion was observed in 9HTeo− pCep-R cells treated with sildenafil (Fig. 6G). Reduction of *P. aeruginosa* adhesion on sildenafil treatment was confirmed in primary human-F508/F508 bronchial epithelial cells (Fig. 6H). Thus pharmacological inhibition of PDE5 corrects both the sialylation and bacterial colonization defects associated with CF respiratory epithelial cells (3, 7, 22, 38).

Another critical aspect of lung pathogenesis in CF is an observation that PDE5 inhibitors can reduce proinflammatory airway responses to LPS (47).

**Sildenafil improves CFTR current.** In addition to analysis of TGN pH, we studied the effect of sildenafil in a mouse nasal potential difference model. In using chamber I∞ studies, nasal mucosae from F508del *Cftr*tm1Eur mice, congenic FVB, were subjected to sildenafil treatment. Sildenafil, in the presence of amiloride, increased I∞ in 5 of 5 mice (10 nasal tissues) tested (+I∞=63 ± 12; Table 1). The effect of sildenafil was most likely mediated via residual-F508 CFTR channels in F508del *Cftr*tm1Eur mice since 1) amiloride was present during sildenafil stimulation, 2) the sildenafil-induced I∞ response in F508del *Cftr*tm1Eur was sensitive to glibenclamide, and 3) the I∞ response to sildenafil was absent in null CFTR−/− transgenic mice (identical genetic background, FVB). Thus sildenafil effects on mucosal tissues from F508 CFTR congenic mice indicate further benefits of Sildenafil treatment, beyond the effects on organellar pH, by enhancing CFTR currents.

**Sildenafil reduces neutrophil lung infiltration in mice aerogenously infected with *P. aeruginosa*.** We tested the effects of sildenafil on relevant inflammatory parameters (neutrophil infiltration, which is a principal cause of lung damage in CF) in an animal model of respiratory exposure to *P. aeruginosa* aerosols (52) using DBA/2 mice sensitive to *P. aeruginosa* (34). No significant protection with sildenafil was detected against mortality in this model of acute infection (n = 90, P = 0.294; Log Rank test). Myeloperoxidase measurements showed reduction in neutrophil infiltrates by 42 ± 11%

### Table 1. In vivo and ex vivo effects of sildenafil on lung mucosal function

<table>
<thead>
<tr>
<th>Experimental Group (DBA/2 mice)</th>
<th>Myeloperoxidase, U/mg lung tissue</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>16.3 ± 1.8</td>
<td>0.047</td>
</tr>
<tr>
<td>Sildenafil</td>
<td>11.4 ± 1.2</td>
<td></td>
</tr>
</tbody>
</table>

In vivo and ex vivo effects of sildenafil on lung mucosal function: improvement of electrolyte currents in tissue explants from CFTR transgenic mice and reduced lung inflammation in aerosol infection model in *P. aeruginosa*-susceptible mice. **Top:** improved chloride currents across mucosae isolated from CF F508del *Cftr*tm1Eur congenic mice. Nasal mucosa from adult F508del *Cftr*tm1Eur mice (congenic FVB, with residual CFTR currents) or CFTR−/− mice (congenic FVB, *Cftr* knockout with no CFTR currents). After equilibration, compounds were added in a standardized order to the mucosal (M) or serosal (S) side of the tissue: 1) indomethacin (10 mM, M+S); to inhibit basal Cl− secretion caused by endogenous production of prostaglandins; 2) amiloride (10 mM, M), to inhibit amiloride-sensitive electrogenic Na+ absorption (reflecting ENaC activity); 3) sildenafil (1 mM, M+S), to inhibit PDE5 and raise intracellular cGMP levels; 4) amiloride was removed by repeated washing to de-inhibit ENaC; 5) sildenafil was again added (1 mM, M+S), and constant current was achieved; 6) amiloride (10 mM, M) was added to measure the ENaC activity in the presence of sildenafil. Assays were performed in duplicate. *N = 5 (F508del *Cftr*tm1Eur, FVB congenic mice). **Sensitive to glibenclamide and equaling 42% of forskolin/cAMP activation (determined in separate experiments). ***Short-circuit current (Isc) response was absent/ negligible in null CFTR−/− transgenic mice (congenic, FVB). Bottom: reduced polymorphonuclear (PMN) leukocyte lung infiltration in the lungs of *P. aeruginosa*-susceptible DBA2 mice placed on a regimen of sildenafil in the diet on aerosol-delivered respiratory infection with *P. aeruginosa*. PMN infiltration was monitored by myeloperoxidase assay in lung homogenates.

---

**Fig. 6.** PDE5 inhibitor sildenafil corrects glycosylation defect, bacterial adherence, and proinflammatory signaling in CF lung epithelial cells. CF cells (IB-3-1 and CFBE41o−), CFTR-corrected CF cells (S9), and normal human bronchial epithelial cells (16HBE14o−) 14 days postconfluence treated for 48 h with zaprinast or sildenafil. A–C: fluorescently stained cells with cholera toxin that binds to properly sialylated GM1 but not to aberrantly nonsialylated aGM1. A: untreated IB-3-1; B: IB-3-1 cell treated with 300 nM sildenafil; C: fluorescence quantification, after background correction (n = 80) relative to normal cells (100%). D and E: fluorescence confocal microscopy of IB-3-1 cells co-transfected with constructs expressing myc-tagged sialyltransferase (α2,3) and normal cells (100%). *L*: treatment with 300 nM sildenafil, performed as previously described (38). Inset: S9 cell. TGN-38-GFP and sialyltransferase remain colocalized as in untreated cells. F–H: PDE5 inhibition (50 μM zaprinast or 300 nM sildenafil) corrects bacterial adhesion. IB-3-1 control, n = 9; CF primary cells, n = 6; all other experimental groups, n = 11. F. NF-κB signaling was measured using a promoter activation luciferase assay, following stimulation with *P. aeruginosa* proinflammatory lipopolipptides (LptA) as described (15). 50 μM zaprinast, n = 3; 300 nM sildenafil, n = 3.
(n = 8, P = 0.047, t-test) at 12 h postexposure in sildenafil-treated animals (Table 1). Effects on mortality in chronic infection (avoiding methods of artificially imposed chronic infection, e.g., by embedding bacteria in agar beads) could not be monitored, since mice either succumbed to naturally delivered acute infection or cleared P. aeruginosa rapidly from the lungs as previously shown (52).

DISCUSSION

The experiments reported here connect the hitherto disparate defects in CF: the lower than normal NO levels (19, 25, 32) and the Na+ transport-dependent hyperacidification of the organellar lumen in CF (37, 38, 40). This work demonstrates, using ENaC knockdowns, the cascade involving NO, cGMP, and ENaC in organellar hyperacidification and dysfunction in CF. This study, along with recent indirect data indicating (39) that a similar pathway operates in the endosomal compartment in CF cells, establishes the cascade of signaling and physiological events explaining several of the principal pathological features in CF. As depicted in the model in Fig. 1C, the lower than normal NO levels in CF respiratory epithelial cells (19, 25, 32) cause suboptimal cGMP levels. The uninhibited ENaC, which is normally blocked by cGMP, results in enhanced Na+ efflux from the organellar lumen in CF. This in turn dissipates the positive charge build-up and allows the proton pump to work excessively, resulting in organellar hyperacidification. This molecular pathological cascade in CF lung cells can be corrected by interventions at several steps along the pathway: by adding exogenous NO, by stimulating guanylate cyclase using agonists, by increasing intracellular cGMP with membrane permeant cGMP analogs, or by incubating the cells with cGMP-specific phosphodiesterase inhibitors. These data also suggest that blocking ENaC by elevating intracellular cGMP may correct the molecular pathological cascade seen in CF lung epithelia cells.

Our laboratory’s recent report (39) suggests that inhibition of PDE5 corrects hyperacidification of recycling endosomes in CF cells in a similar fashion to the processes reported here. It is likely that the pertinent signaling pathways, delineated in the present study for the TGN, apply to other organelles in which ENaC and sodium fluxes play a role, including endosomes in CF respiratory epithelial cells (40). Furthermore, a study by Dormer and colleagues has indicated that sildenafil affects F508-CFTR localization in nasal epithelial cells (13). The concentration of sildenafil used by Dormer et al. (13) ranged from 150 μM for correction of CFTR trafficking to 1 mM for correction of chloride channel activity. This exceeds by far the more pharmacologically relevant concentrations used in our study (300 mM sildenafil), which matches plasma levels achieved in standard sildenafil use in humans. Nevertheless, the previously published studies (13, 39) and the present work point to the potentially beneficial action of sildenafil in CF.

Our study demonstrates that pharmacological inhibition of PDE5 corrects a succession of interconnected defects in CF respiratory epithelial cells. Moreover, the pathological manifestations of the pH defect (37, 38, 40) are corrected by sildenafil treatment. This includes 1) undersialylation of plasma membrane glycoconjugates, 2) bacterial adhesion, 3) excessive proinflammatory response, 4) electrolyte transport across respiratory mucosa, and 5) lung inflammation in response to CF-specific bacterial pathogen. The observation that a sequence of abnormalities in CF can be connected as shown in the present study indicates that a common root to the clinically relevant problems can be identified. It is equally important, that this chain of pathological consequences can be corrected or ameliorated by clinically proven PDE5 inhibitors. Since this can be achieved with low, therapeutic doses of sildenafil as shown in the present study, our findings represent a step toward clinical trials with sildenafil in CF.

ACKNOWLEDGMENTS

We thank P. Karp and J. Zabner for primary bronchial epithelial cells from CF patient lungs, and P. Davis, D. Gruenert, and P. Zeitlin for cell lines. We thank A. Verkman for the specific CFTR chloride channel inhibitor CFTRinh-172.

GRANTS

This work was supported by National Institutes of Health Grants R01 AI-50825 and R01 AI-31139, and by Philip Morris USA and Philip Morris International to V. Deretic and R15 DK-58128 from National Institutes of Health and YU0401 from Cystic Fibrosis Foundation (CFF) to H. D. Yu. J. F. Poschet and W. Oratowski were CFF postdoctoral fellows. GST was supported by a CFF grant.

REFERENCES

Pharmacological modulation of cGMP levels in CF

L719


